Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Current Size And Growth Outlook For The Humira Biosimilar Market?

The size of the Humira biosimilar market has seen a swift expansion in recent years. The market, valued at $3.28 billion in 2024, is projected to increase to $3.67 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.0%. The historic period’s growth owes much to the escalating demand for more affordable alternatives, an increase in the approval of biosimilars by regulatory bodies, a rise in the occurrence of autoimmune diseases, improved access to healthcare in developing markets, and the steep pricing of original biologics.

The market for Humira biosimilars is predicted to experience significant expansion in the forthcoming years, with projections estimating its growth to reach $5.82 billion by 2029, marking a 12.3% Compound Annual Growth Rate (CAGR). This anticipated expansion during the forecast period can be credited to improvements in biosimilars’ development technology, escalating efforts to contain healthcare costs, proliferating patent expiries of original biologics, betterments in market accessibility and reimbursement policies and an increased implementation of biosimilars in fields like oncology and autoimmune disorders. The forecast period will also witness significant trends such as rising approval rates for additional biosimilars, progress in manufacturing techniques, amplified research and developmental activities, and the advancement of biosimilar drug formulation and approval.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24244&type=smp

What Core Drivers Are Expected To Influence The Humira Biosimilar Market?

The humira biosimilar market is predicted to expand owing to the rising incidence of autoimmune diseases. These diseases occur when the body’s own immune system mistakenly destroys its healthy cells, tissues, or organs. The surge in autoimmune diseases has been attributed to environmental pollution, which compromises the immune system, leading to an increased risk of autoimmune responses. The function of Humira biosimilars is to obstruct tumor necrosis factor (TNF), a protein creating inflammation in autoimmune conditions. This process lessens the immune response, relieves symptoms, and stops damage to healthy tissues. For instance, a government organization based in Australia, the Australian Institute of Health and Welfare, in June 2024, estimated that in 2022, 514,000 individuals (2.0%) in Australia were diagnosed with rheumatoid arthritis. This affected 2.5% of the female population and 1.6% of males. Hence, the growing occurrence of autoimmune diseases is fueling the growth of the humira biosimilar market.

Which Segmentation Categories Are Highlighted In The Humira Biosimilar Market Analysis?

The humira biosimilarmarket covered in this report is segmented –

1) By Product Type: Adalimumab Biosimilars; Other Types

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels

3) By Application: Rheumatoid Arthritis; Psoriasis; Crohn’s Disease; Ulcerative Colitis; Ankylosing Spondylitis; Other Applications

Subsegments:

1) By Adalimumab Biosimilars: Fully Human Monoclonal Antibodies; Fragment Crystallizable (Fc) Region Modified Biosimilars; High-Concentration Formulations; Citrate-Free Formulations

2) By Other Types: Biosimilars Of Other Tumor Necrosis Factor (TNF) Inhibitors; Interchangeable Biosimilars; Pegylated Biosimilars; Non-Adalimumab Monoclonal Antibody Biosimilars

Which Market Trends Are Expected To Define The Future Of The Humira Biosimilar Market?

Big players in the humira biosimilar market are honing their focus on the creation of superior products, such as tumor necrosis factor (TNF) blockers, to enable more cost-friendly autoimmune disease treatment solutions. TNF blockers, biological drugs, are designed to mitigate the influence of TNF, a central protein that contributes to inflammation. For example, in July 2023, American pharmaceutical company, Organon & Co., joined forces with South Korean biotechnology enterprise, Samsung Bioepis Co., Ltd., to unveil HADLIMA, a parallel biosimilar of Humira. HADLIMA is obtainable in both citrate-free high-concentration (100 mg/mL) and citrate-containing low-concentration (50 mg/mL) presentations, mirroring the choices of the original Humira, with the intention of enhancing patient accessibility and cost-effectiveness. The product is sold at a significantly reduced price, approximately 85% less than Humira’s standard rate, and offers patient support programs. This launch, following a global settlement that allows U.S. supply, symbolizes a considerable breakthrough in broadening treatment possibilities for chronic autoimmune disorders in the U.S.

Who Are The Dominant Players In The Humira Biosimilar Market Today?

Major companies operating in the humira biosimilar market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., LG Chem Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Mylan N.V., Sandoz Group AG, Fresenius Kabi AG, Celltrion Inc., Biocon Limited, Torrent Pharmaceuticals, Samsung Bioepis Co. Ltd., Alvotech, Coherus BioSciences Inc., Zydus Cadila, Hetero Drugs Ltd., Fujifilm Kyowa Kirin Biologics, Synermore Biologics, CVS Health.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/humira-biosimilar-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Humira Biosimilar Market?

North America was the largest region in the humira biosimilar market in 2024. The regions covered in the humira biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=24244&type=smp

Browse Through More Reports Similar to the Global Humira Biosimilar Market 2025, By The Business Research Company

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Granulocyte Colony Stimulating Factors Market 2025

https://www.thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market

Drug Delivery Devices Market 2025

https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model